CLINICAL AND IMMUNOHISTOCHEMICAL FEATURES OF PRIMARY BREAST CANCER AND METACHRONOUS OVARIAN AND ENDOMETRIAL TUMORS

The aim of the study was to assess the patterns of development of metachronous cancer (endometrial cancer, EC, and ovarian cancer, OC) in breast cancer (BC) patients dependent of receptor phenotype of breast tumors. Materials and Methods: In the study, 63 patients with ВС, who developed metachronous EC (n = 47) or OC (n = 16) were enrolled. Expression of estrogen receptor (ER), progesterone receptor (PR), HER/2neu was assessed using immunohistochemical approach. Results: BC in patients with metachronous EC and OC was characterized by a different frequency of molecular subtypes with the dominance of luminal A (36%) and B (43%) subtypes. In primary BC, we have established a correlation between ER expression and regional lymph nodes status (r = −0.50, p < 0.05); negative correlation between HER2/neu expression and tumor stage (r = −0.48, p < 0.05); between the molecular subtype of BC and its size (r = −0.33, p <0.05), the molecular subtype of primary BC and metastases in regional lymph nodes (r = 0.27, p <0.05). In the patients with luminal subtype BC metachronous tumors developed with the highest frequency (OC — 50%, EC — 50%). After treatment of primary BC metachronous tumors developed at different period: EC (22.2%) — most often in 3–5 years, OC (11.0%) — after 10 years and more. Conclusion: Our data evidence on the clinical significance of the individual characteristics of the BC, especially its molecular subtype, and the need to calculate the personalized risk of development of metachronous tumors of the reproductive system in patients with the BC.

Download Full-text

Serum HIF-1α and TGFβ1 levels depending on the clinical and morphological characteristics of breast cancer and sensitivity of tumor to neoadjuvant chemotherapy

Research n Practical Medicine Journal ◽

10.17709/2410-1893-2021-8-4-5 ◽

2021 ◽

Vol 8 (4) ◽

pp. 52-64

Author(s):

E. Yu. Zubareva ◽

M. A. Senchukova ◽

E. V. Virich ◽

M. R. Zubarev ◽

M. A. Goncharova

Keyword(s):

Breast Cancer ◽

Lymph Nodes ◽

Triple Negative ◽

Morphological Characteristics ◽

Distant Metastases ◽

Luminal A ◽

Her2 Positive ◽

Regional Lymph Nodes ◽

Tgf Β1 ◽

Grade Iii

Purpose of the study. To assess the serum levels of HIF-1 α and TGF-β1 in patients with invasive breast cancer (BC) depending on the clinical and morphological characteristics, molecular biological subtypes and the degree of pathological response (PR) of the tumor and metastases in the regional lymph nodes.Materials and methods. 65 patients with newly diagnosed invasive BC, of whom 32 received from 6 to 8 courses of neoadjuvant chemotherapy (neo-A-CT) were included in this pilot study. The levels of TGF-β1 and HIF-1α were determined by enzyme-linked immunosorbent assay. Statistical analysis was performed using the Statistica 12.0 software.Results. It was found that a high level of TGF-[31 was significantly more often observed in HER2-positive and I-IIa stages of luminal A and triple-negative BC (p = 0.01). HIF-1a levels were significantly higher in the presence of distant metastases (p = 0.04) and slightly higher in the presence of microcalcifications on mammograms (p = 0.07).The analysis showed that patients with grade III-IV of PR in tumor were significantly younger (p = 0.047). Grade III-IV of PR in tumor was significantly more often observed in G3 (p = 0.05), in Her2-positive and triple negative BC (p = 0.01), in the absence of perineural (p = 0.002) and lymphovascular invasion (LVI) (p = 0.045), in the presence of lymphoid infiltration (p = 0.011) and microcalcifications in the tumor (p = 0.043), and slightly higher in ductal BC (p = 0.08). No significant correlations were found between the levels of TGF-p1 and HIF-1a and tumor PR (p = 0.6 and p = 0.9, respectively). However, in patients with grade III-IV of PR in regional metastases, the level of TGFb1 was significantly lower than in patients with grade I-II (p = 0.03).Conclusions. Thus, these data indicate the presence of correlations between the levels of HIF-1 α and TGF-β1 in the blood serum and a number of clinical characteristics of BC. The highest levels of HIF-1α are observed in the presence of distant metastases, and the highest levels of TGF-β1 are noted in HER2-positive and I-IIa stages of luminal A and triple-negative breast cancer. Given the presence of significant correlations between the level of TGF-β1 and the degree of PR in regional lymph nodes, its determination may be useful for assessing the sensitivity of metastases to regional lymph nodes to the neo-A-CT.

Download Full-text

СD44+/CD24− MARKERS OF CANCER STEM CELLS IN PATIENTS WITH BREAST CANCER OF DIFFERENT MOLECULAR SUBTYPES

Experimental Oncology ◽

10.31768/2312-8852.2015.37(1):58-63 ◽

2015 ◽

Vol 37 (1) ◽

pp. 58-63 ◽

Cited By ~ 11

Author(s):

V F Chekhun ◽

T V Zadvorny ◽

Yu O Tymovska ◽

M F Anikusko ◽

O E Novak ◽

...

Keyword(s):

Breast Cancer ◽

Stem Cells ◽

Cancer Stem Cells ◽

Molecular Subtypes ◽

Molecular Subtype ◽

Statistical Processing ◽

Stage I ◽

Poor Correlation ◽

Luminal A ◽

Regional Lymph Nodes

Aim: To determine frequency of tumors with immunohistochemical markers of cancer stem cells (CSC) CD44+/CD24− in patients with breast cancer (BC) of different molecular subtype and to evaluate their prognostic value. Object: Surgical material of 132 patients with BC stage I–II, age from 23 to 75 years, mean age — 50.2 ± 3.1 years was studied. Methods: Clinical, immunohistochemical (expression CD44+/CD24−), morphological, statistical. Results: BC is characterized by heterogeneity of molecular subtypes and expression of markers (CD44+/CD24−). Immunohistochemical study of expression of CSC markers in surgical material has detected their expression in 34 (25.4%) patients with BC of different molecular subtypes. The highest frequency of cells with expression of CSC marker was observed in patients with basal molecular subtype (44.8% patients). Most of BC patients with phenotype CD44+/CD24 had stage I of tumor process (34.3%). Statistical processing of data has showen that Yule colligation coefficient equaled 0.28 (р > 0.05) that argues poor correlation between stage of tumor process and number of tumors with positive expression of CSC markers. Statistical processing of data has showen high correlation between presence of cells with expression of CSC markers and metastases of BC in regional lymph nodes (Yule colligation coefficient equals 0.943; р < 0.5). Difference in overall survival of patients with BC of basal molecular subtype depending on expression of CSC CD44+/CD24− markers was detected. Survival of patients with basal BC was reliably higher at lack in tumors of cells with CSC markers CD44+/CD24− and, correspondingly, lower at presence of such cells (р < 0.05). In patients with BC of luminal (A and B), HER-2-positive subtypes, significant change in survival of patients depending on expression of CSC markers was not determined (р > 0.05). Conclusion: Significance of tumor cells with markers CD44+/CD24− within the limits of molecular subtype of BC may be additional criterion for advanced biological characteristic of BC, and in patients with BC of basal molecular subtype — for predictive evaluation of individual potential of tumor to aggressive clinical course.

Download Full-text

Karakteristik Histopatologik dan Imunofenotipik Kanker Payudara di Rumah Sakit Cipto Mangunkusumo Jakarta, Indonesia

Medicinus ◽

10.19166/med.v6i3.1147 ◽

2018 ◽

Vol 6 (3) ◽

Author(s):

Primariadewi Rustamadji ◽

Stephanie Marisca

Keyword(s):

Breast Cancer ◽

Molecular Subtype ◽

Breast Cancer Subtype ◽

Breast Cancer Case ◽

Tumor Stage ◽

Cancer Case ◽

Genetic Profile ◽

Luminal A ◽

Cross Sectional ◽

Luminal B

Introduction: Breast cancer can be classified into luminal A, luminal B, Her2+, dan basal-like molecular subtype according to genetic profile and immunophenotype. The aim of this study is to assess histopathologic and immunophenotype characteristics of breast cancer in Cipto Mangunkusumo Hospital Jakarta, Indonesia. Material and methods: This study is a cross-sectional retrospective study. The sample was 2632 breast cancer case in Department of Anatomical Pathology Cipto Mangunkusumo Hospital from the year 2011 until 2015. ER, PR, Her2, Top2 α, and Ki67 immunohistochemical stain was then grouped into luminal A (ER+/PR+/Her2-/Ki67<20%) subtype, luminal B (ER+/PR+/Her2-/Ki67≥20%) subtype, Her2+ (ER-/PR-/Her2+) subtype, and basal-like (ER-/PR-/Her2-) subtype. Kendall’s Tau analysis was done to assess association between sample characteristics and molecular subtype, association between top2α positive and molecular subtype. Result: The most prevalent to the less prevalent breast cancer molecular subtype was luminal B (43,9%), Her2+ (14,6%), luminal A (14,0%), and basal-like (11,3%). There was a significant association between the tumor stage and breast cancer subtype (p=0,0001). There is also a significant association between Top2α expression and molecular subtype (p=0,0001). Conclusion: The most prevalent breast cancer molecular subtype was luminal B. There was an association between breast cancer molecular subtype and a higher degree and Top2α expression.

Download Full-text

Breast Cancer Clinical Regional Lymph Nodes TNM Finding v8

10.32388/akyy54 ◽

2020 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Lymph Nodes ◽

Regional Lymph Nodes

Download Full-text

Hybrid volumetric-modulated arc therapy for postoperative breast cancer including regional lymph nodes: the advantage of dosimetric data and safety of toxicities

Journal of Radiation Research ◽

10.1093/jrr/rraa057 ◽

2020 ◽

Vol 61 (5) ◽

pp. 747-754

Author(s):

Yoshiko Doi ◽

Minoru Nakao ◽

Hideharu Miura ◽

Shuichi Ozawa ◽

Masahiro Kenjo ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Nodes ◽

Irradiation Dose ◽

Organs At Risk ◽

Volumetric Modulated Arc Therapy ◽

Conformity Index ◽

Regional Lymph Nodes ◽

Dosimetric Data ◽

Arc Therapy

ABSTRACT To improve the homogeneity and conformity of the irradiation dose for postoperative breast cancer including regional lymph nodes, we planned Hybrid volumetric-modulated arc therapy (VMAT), which combines conventional tangential field mainly for the chest area and VMAT mainly for the supraclavicular area and marginal zone. In this study, we compared the dosimetric impact between traditional 3D conformal radiotherapy (3DCRT) and Hybrid VMAT and observed toxicities following Hybrid VMAT. A total of 70 patients indicated between October 2016 and December 2017 were included. The prescribed dose was 50 Gy/25 fractions. For the dosimetric impact, 3DCRT and Hybrid VMAT plans were compared in each patient with respect to the dosimetric parameters. Toxicities were followed using the Common Terminology Criteria for Adverse Events version 4.0. The median follow-up duration was 319 days. For the dosimetric impact, the homogeneity index (HI) and conformity index (CI) of PTV were significantly improved in the Hybrid VMAT plan compared with that in the 3DCRT plan (HI, 0.15 ± 0.07 in Hybrid VMAT vs 0.41 ± 0.19 in 3DCRT, P < 0.001; CI, 1.61 ± 0.44 in Hybrid VMAT vs 2.10 ± 0.56 in 3DCRT, P < 0.001). The mean irradiated ipsilateral lung dose was not significantly different in both plans (12.0 ± 2.4 Gy in Hybrid VMAT vs 11.8 ± 2.8 Gy in 3DCRT, P < 0.533). Regarding toxicity, there were no patients who developed ≥grade 3 acute toxicity and ≥grade 2 pneumonitis during the follow-up. Hybrid VMAT for postoperative breast cancer including regional lymph nodes was a reasonable technique that improved the homogeneity and conformity of the irradiation dose to the planning target volume while keeping the irradiation dose to organs at risk to a minimum.

Download Full-text

Surgical component of lateral and central breast cancer treatment

Kazan medical journal ◽

10.17816/kmj2021-479 ◽

2021 ◽

Vol 102 (4) ◽

pp. 479-485

Author(s):

Z M Abdurakhmanova ◽

M R Ramazanov ◽

E I Sigal

Keyword(s):

Breast Cancer ◽

Lymph Nodes ◽

Oxygen Saturation ◽

Cancer Treatment ◽

Comparison Group ◽

Breast Cancer Treatment ◽

Main Group ◽

Regional Lymph Nodes ◽

Hemoglobin Oxygen Saturation ◽

Arterial Blood

Aim. To improve the results of the surgical component in the treatment of a nodular form of breast cancer with lateral and central localization by analyzing hemoglobin oxygen saturation of arterial blood in the foci of breast cancer, regional lymph nodes and resection line of the breast. Methods. The study involved 175 patients with a nodular form of breast cancer with lateral and central localization (T23N12M0), including 86 in the main group and 89 in the comparison group. In the main group, hemoglobin oxygen saturation in arterial blood of the foci of breast cancer, parenchyma, pectoral muscles and regional lymph nodes was examined for spread of cancer during surgery for nodular breast cancer by using a device developed by us (patent RU 2581266). This examination was not performed in the comparison group. Histopathological examination of resection specimens revealed confirmation of the main foci of breast cancer and the presence of metastases in the regional lymph nodes and pectoral muscles of the breast. Statistical analysis of the data was performed by using the Statistica 10 software. The arithmetic mean, the standard error of the mean and the standard deviation were calculated for the quantitative indicators. Results. In the main group, 86 patients had no recurrence and metastases in the follow-up, while in the comparison group, cancer recurrence was identified in 89 patients and metastases was found during cytological and histological studies in 9 patients. Conclusion. Determination of hemoglobin oxygen saturation of arterial blood during surgery in the subclavian, axillary and subscapular lymph nodes as well as in the pectoralis major and minor muscles allows clarifying the distribution of breast cancer, specifying the scope of the operation and improving the results of the surgical component of breast cancer treatment (T23N12M0).

Download Full-text

Differential expression of mab-21 like 1 in cancers of the breast.

10.31219/osf.io/2gkba ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Survival Data ◽

Molecular Subtype ◽

Differentially Expressed Gene ◽

Normal Breast ◽

Differentially Expressed ◽

Luminal A ◽

Significant Differential Expression ◽

Primary Tumors

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding mab-21 like 1, MAB21L1, when comparing primary tumors of the breast to the tissue of origin, the normal breast. MAB21L1 was also differentially expressed in the tumor cells of patients with triple negative breast cancer. MAB21L1 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of MAB21L1 in primary tumors of the breast was correlated with overall survival in patients with luminal A subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by molecular subtype. MAB21L1 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

Download Full-text

Differential expression of defective in cullin neddylation 1 domain-containing 3 in cancers of the breast.

10.31219/osf.io/wgcqv ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Survival Data ◽

Molecular Subtype ◽

Differentially Expressed Gene ◽

Normal Breast ◽

Differentially Expressed ◽

Luminal A ◽

Significant Differential Expression ◽

Primary Tumors

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding defective in cullin neddylation 1 domain-containing 3, DCUN1D3, when comparing primary tumors of the breast to the tissue of origin, the normal breast. DCUN1D3 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of DCUN1D3 in primary tumors of the breast was correlated with recurrence-free survival in patients with basal, luminal A and luminal B subtype cancers, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by PAM50 molecular subtype. DCUN1D3 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

Download Full-text

Clinical, morphological, and molecular genetic predictors of metastatic lesions in the regional lymph nodes in breast cancer

Advances in molecular oncology ◽

10.17650/2313-805x-2018-5-3-8-16 ◽

2018 ◽

Vol 5 (3) ◽

pp. 8-16

Author(s):

Yu. A. Dergunova ◽

V. V. Podionov ◽

V. K. Bozhenko ◽

V. V. Kometova ◽

M. V. Dardyk

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Lymph Nodes ◽

Molecular Genetic ◽

Regional Lymph Nodes ◽

Genetic Characteristics ◽

Metastatic Lesions ◽

Genetic Predictors ◽

Node Metastases ◽

High Degree

Despite the sufficient amount of data accumulated in the literature, there are still no factors, on the basis of which it would be possible to estimate the regional lymph nodes status in breast cancer with a high degree of accuracy. The review presents literature data relating to the influence of clinicopathological, molecular-biological and genetic characteristics of primary tumor on lymph node metastases. Data of 66 foreign and Russian articles are included.

Download Full-text

Differential expression of dystrophin in cancers of the breast.

10.31219/osf.io/yn2xe ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Survival Data ◽

Molecular Subtype ◽

Differentially Expressed Gene ◽

Normal Breast ◽

Differentially Expressed ◽

Luminal A ◽

Significant Differential Expression ◽

Primary Tumors

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding dystrophin, DMD, when comparing primary tumors of the breast to the tissue of origin, the normal breast. DMD was also differentially expressed in the tumor cells of patients with triple negative breast cancer. DMD mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of DMD in primary tumors of the breast was correlated with overall survival in patients with basal and luminal A subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by molecular subtype. DMD may be of relevance to initiation, maintenance or progression of cancers of the female breast.

Download Full-text